Skip to main content

Advertisement

SpringerLink
Log in

Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The relationship between plasma levels of total phospholipids (PL) and/or PL fractions and neoplastic diseases are not fully understood. Therefore, the aim of this study was to analyze concentrations and distribution of plasma phospholipids in patients with prostate cancer (PCa) related to the Gleason score, clinical stage and pathologic grade of prostate cancer. We analyzed plasma phospholipids in 57 newly diagnosed, untreated PCa patients and in 43 age-matched healthy male subjects. Significantly lower (P < 0.01) levels of total plasma PL and all PL classes were found in PCa patients when compared with healthy subjects. The relative concentrations of PL fractions were also changed. Further decrease of total PL and PL fractions was found related to an increase of clinical stadium, pathologic grade, and Gleason score, with phosphatidylethanolamine as the most sensitive plasma PL, the level of which significantly decreased even at the first stage of PCa. Our results showed an altered plasma PL profile in PCa patients, which may contribute to monitoring of the disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wright MM, Howe AG, Zaremberg V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem Cell Biol. 2004;82(1):18–26.

    Article  PubMed  CAS  Google Scholar 

  2. Wolf C, Quinn PJ. Lipidomics: practical aspects and applications. Prog Lipid Res. 2008;47(1):15–36.

    Article  PubMed  CAS  Google Scholar 

  3. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26:1015–35.

    PubMed  CAS  Google Scholar 

  4. Tepsic J, Vucic V, Arsic A, Blazencic-Mladenovic V, Mazic S, Glibetic M. Plasma and erythrocyte phospholipid fatty acid profile in professional basketball and football players. Eur J Appl Physiol. 2009;107(3):359–65.

    Article  PubMed  CAS  Google Scholar 

  5. Kim H, Min HK, Kong G, Moon MH. Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem. 2009;393(6–7):1649–56.

    Article  PubMed  CAS  Google Scholar 

  6. Min HK, Kong G, Moon MH. Quantitative analysis of urinary phospholipids found in patients with breast cancer by nanoflow liquid chromatography-tandem mass spectrometry: II. Negative ion mode analysis of four phospholipid classes. Anal Bioanal Chem. 2010;396(3):1273–80.

    Article  PubMed  CAS  Google Scholar 

  7. Preetha A, Banerjee R, Huilgol N. Surface activity, lipid profiles and their implications in cervical cancer. J Cancer Res Ther. 2005;1(3):180–6.

    Article  PubMed  CAS  Google Scholar 

  8. Cvetkovic Z, Cvetkovic B, Petrovic M, et al. Lipid profile as a prognostic factor in cancer patients. J BUON. 2009;14(3):501–6.

    PubMed  CAS  Google Scholar 

  9. Sullentrop F, Moka D, Neubauer S, et al. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002;15(1):60–8.

    Article  PubMed  CAS  Google Scholar 

  10. Taylor LA, Arends J, Hodina AK, Unger C, Massing U. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007;6:17.

    Article  PubMed  Google Scholar 

  11. Kuliszkiewicz-Janus M, Janus W, Baczynski S. Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 1996;161(3B):1587–94.

    Google Scholar 

  12. Raffelt K, Moka D, Sullentrop F, Dietlein M, Hahn J, Schicha H. Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in vitro (31)P high-resolution NMR study. NMR Biomed. 2000;13(1):8–13.

    Article  PubMed  CAS  Google Scholar 

  13. Grubb RL 3rd, Kibel AS. Prostate cancer: screening, diagnosis and management in 2007. Mo Med. 2007;104(5):408–13. quiz 413–414.

    PubMed  Google Scholar 

  14. Vucic V, Niciforovic A, Adzic M, Radojcic MB, Ruzdijic S. The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells. Invest New Drugs. 2008;26(4):309–17.

    Article  PubMed  CAS  Google Scholar 

  15. Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal. 2010;10:1919–31.

    Article  PubMed  CAS  Google Scholar 

  16. Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol. 2004;28(7):946–52.

    Article  PubMed  Google Scholar 

  17. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989;141(5):1088–90.

    PubMed  CAS  Google Scholar 

  18. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.

    PubMed  CAS  Google Scholar 

  19. American Joint Committee on Cancer (AJCC), et al. Prostate. In: Greene FL, Pge DL, Fleming ID, Fritz AG, Balch CM, editors. AJCC cancer staging manual, vol. 6. New York (NY): Springer; 2002. p. 309–16.

    Google Scholar 

  20. Marinovic V, Nedic O, Stanojevic N, Baricevic I, Pavlica S. Investigation of the relationship between two major prostate tumour markers. Yugoslav Med Biochem. 2000;19(4):407–10.

    CAS  Google Scholar 

  21. Zilversmit DB, Davis AK. Microdetermination of plasma phospholipids by trichloroacetic acid precipitation. J Lab Clin Med. 1950;35(1):155–60.

    PubMed  CAS  Google Scholar 

  22. Ristic V, Tepsic V, Ristic-Medic D, et al. Plasma and erythrocyte phospholipid fatty acids composition in Serbian hemodialyzed patients. Ren Fail. 2006;28(3):211–6.

    Article  PubMed  CAS  Google Scholar 

  23. Marinetti GV, Albrecht M, Ford T, Stotz E. Analysis of human plasma phosphatides by paper chromatography. Biochim Biophys Acta. 1959;36:4–13.

    Article  PubMed  CAS  Google Scholar 

  24. Khuu Thi-Dinh KL, Demarne Y, Nicolas C, Lhuillery C. Effect of dietary fat on phospholipid class distribution and fatty acid composition in rat fat cell plasma membrane. Lipids. 1990;25(5):278–83.

    Article  PubMed  CAS  Google Scholar 

  25. Zeghari N, Younsi M, Meyer L, Donner M, Drouin P, Ziegler O. Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia: a study in nondiabetic and diabetic obese women. Int J Obes Relat Metab Disord. 2000;24(12):1600–7.

    Article  PubMed  CAS  Google Scholar 

  26. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599–603.

    PubMed  CAS  Google Scholar 

  27. Kuliszkiewicz-Janus M, Baczynski S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn Reson Med. 1996;35(4):449–56.

    Article  PubMed  CAS  Google Scholar 

  28. Kuliszkiewicz-Janus M, Baczynski S. Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim Biophys Acta. 1997;1360(1):71–83.

    PubMed  CAS  Google Scholar 

  29. Cvetkovic Z, Vucic V, Cvetkovic B, et al. Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol. 2010;89(8):775–82.

    Article  PubMed  CAS  Google Scholar 

  30. Murphy RA, Wilke MS, Perrine M, et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin Nutr. 2010;29(4):482–7.

    Article  PubMed  CAS  Google Scholar 

  31. Marra CA, de Alaniz MJ. Regulatory effect of various steroid hormones on the incorporation and metabolism of [14C]stearate in rat hepatoma cells in culture. Mol Cell Biochem. 1995;145(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  32. Koo JM, Shim BS. Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml. Korean J Urol. 2010;51(12):831–5.

    Article  PubMed  Google Scholar 

  33. Morote J, Planas J, Ramirez C, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010;105(4):481–4.

    Article  PubMed  CAS  Google Scholar 

  34. Zhao Z, Xiao Y, Elson P, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007;25(19):2696–701.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Project 41030 financed by the Ministry of Science of the Republic of Serbia.

Conflict of interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Urology, Clinical Hospital Center Zemun, Vukova 9, 11080, Belgrade, Serbia

    B. Cvetković

  2. Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Tadeusa Koscuska 1, 11129, Belgrade, Serbia

    V. Vučić, T. Popović & M. Glibetić

  3. Department of Hematology, Clinical Hospital Center Zemun, Vukova 9, 11080, Belgrade, Serbia

    Z. Cvetković

Authors
  1. B. Cvetković
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Vučić
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. Cvetković
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Popović
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Glibetić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Vučić.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cvetković, B., Vučić, V., Cvetković, Z. et al. Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients. Med Oncol 29, 809–814 (2012). https://doi.org/10.1007/s12032-011-9914-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9914-z

Keywords

Search

Navigation